Matthew Perry

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

BVF, Inc. manages engages in investment business and manages biotech focused hedge funds. The firm manages Biotechnology Value Fund LP and Biotechnology Value Fund II LP. The company was founded by Mark Nathan Lampert on September 14, 1993 and is headquartered in San Francisco, CA.

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.

Part of Ogilvy Government Relations, Feinstein Kean Partners, Inc. is a public relations firm. The company is based in Cambridge, MA. Feinstein Kean Partners was acquired by Ogilvy Public Relations Worldwide, Inc. on November 08, 1999.

Feinstein Kean Healthcare is a private company that provides strategic communications consulting services. The company is based in Cambridge, MA.

Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom.

Nordic Biotech Advisors ApS (NB Capital) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2001 by Florian Schönharting and Dr. Christian Hansen, and is owned by a group of institutional investors.

Part of BVF, Inc., Biotechnology Value Fund LP is an Alternative Investment Manager. The company is based in San Francisco, CA.